UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at HC Wainwright

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $60.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 376.95% from the company’s previous close.

Other equities research analysts have also recently issued reports about the stock. Guggenheim assumed coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price target on the stock. LADENBURG THALM/SH SH upped their target price on UroGen Pharma from $48.00 to $53.50 and gave the stock a “buy” rating in a report on Friday, June 14th. Finally, Oppenheimer raised their price target on UroGen Pharma from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, June 14th.

UroGen Pharma Stock Up 0.8 %

NASDAQ:URGN opened at $12.58 on Thursday. The stock has a 50-day simple moving average of $14.19 and a 200 day simple moving average of $14.56. UroGen Pharma has a 52-week low of $10.60 and a 52-week high of $20.70. The company has a market cap of $295.05 million, a PE ratio of -3.70 and a beta of 1.11. The company has a debt-to-equity ratio of 3.23, a quick ratio of 7.93 and a current ratio of 8.15.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The firm had revenue of $21.85 million for the quarter, compared to the consensus estimate of $23.69 million. On average, sell-side analysts expect that UroGen Pharma will post -3.49 EPS for the current fiscal year.

Institutional Investors Weigh In On UroGen Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Coastal Bridge Advisors LLC increased its position in UroGen Pharma by 4.1% during the second quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company’s stock worth $646,000 after buying an additional 1,500 shares during the last quarter. Millennium Management LLC raised its stake in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after acquiring an additional 1,119,019 shares during the period. Point72 Asset Management L.P. lifted its holdings in UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after purchasing an additional 1,337,257 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in UroGen Pharma by 630.9% during the second quarter. Cubist Systematic Strategies LLC now owns 44,949 shares of the company’s stock worth $754,000 after purchasing an additional 38,799 shares during the period. Finally, Great Point Partners LLC boosted its position in UroGen Pharma by 10.9% during the second quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock worth $48,767,000 after purchasing an additional 285,714 shares during the period. 91.29% of the stock is owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.